우르소데옥시콜산
우르소데옥시콜산 · 우르소다이올 · UDCA · URSODIOL · Ursodeoxycholic · URSODESOXYCHOLIC ACID · URSODEOXYCHOLATE · Tauroursodiol
식별자 및 물리적 특성
| CAS No. | 128-13-2 |
|---|---|
| 분자식 | C24H40O4 |
| 평균 분자량 | 392.6 g/mol |
| 단동위원소 질량 | 392.29265975 g/mol |
| SMILES | C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |
| InChIKey | RUDATBOHQWOJDD-UZVSRGJWSA-N |
| PubChem CID | 31401 |
| ChEMBL | CHEMBL1551 |
| ChEBI | CHEBI:9907 |
| EC No. | 204-879-3 |
| DTXSID | DTXSID6023731 |
| 현지명 | 우르소데옥시콜산 |
화학 및 물리적 성질
| XLogP | 4.9 |
|---|---|
| 극성 표면적 | 77.8 |
| 수소 결합 공여자 수 | 3 |
| 수소 결합 수용자 수 | 4 |
| 회전 가능 결합 수 | 4 |
| 무거운 원자 수 | 28 |
| 형식 전하 | 0 |
| 복잡도 | 605 |
| LogP(분배 계수) | 33.00 |
| 용해도 | 0.02 mg/mL에탄올: 50mg/mL, 투명 |
| 녹는점 | 200-205203 °C203-204 °C (lit.) |
| Physical Description | Solid |
| Collision Cross Section | 200.0 Ų [M-H]- [CCS Type: DTBuffer gas: N2Ionization: ESI-Dataset: Bile Acids]208.98 Ų [M-H]- [CCS Type: DTMethod: stepped-field]200.9 Ų [M-H]- [CCS Type: DTMethod: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]198.7 Ų [M+Na]+ [CCS Type: DT203.2 Ų [M+Na-H+HCOO]- [CCS Type: DTMethod: single field calibrated]198.3 Ų [M-H]- [CCS Type: DT199.4 Ų [M+Na-H+Cl]- [CCS Type: DT186.8 Ų [M+H-2H2O]+ [CCS Type: DT200.2 Ų [M+HCOO]- [CCS Type: DT205.7 Ų [M+K-H+HCOO]- [CCS Type: DT198.86 Ų [M+K]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]193.71 Ų [M+H]+ [CCS Type: TW196.65 Ų [M+Na]+ [CCS Type: TW |
| 끓는 점 | 437.26°C (rough estimate) |
| 밀도 | 0.9985 (rough estimate) |
| 굴절률 | 60.5 ° (C=2, EtOH) |
| 인화점 | 9℃ |
| 저장 조건 | 2-8°C |
| 물리적 상태 | 단단한. 가루. |
| pKa(산도 계수) | pKa 5.04±0.04(H2O t = 25.0±0.1 I = 0.00)(Approximate) |
| 색상 | 흰색 - 거의 흰색입니다. |
| 용해도 | 실질적으로 불용성 |
| Merck | 14,9889 |
| BRN | 3219888 |
| 화장품 원료 기능 | 피부 컨디셔닝 - 기타피부 보호 |
| InChIKey | RUDATBOHQWOJDD-UZVSRGJWSA-N |
| SMILES | C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |
| LogP(분배 계수) | 3-3.38 at 20℃ |
화학적 성질
WHITE CRYSTALLINE POWDER
안전 및 규제
| GHS 분류 | This chemical does not meet GHS hazard criteria for 4.5% (2 of 44) of reports.WarningH315 (95.5%): Causes skin irritation [Warning Skin corrosion/irritation]H319 (95.5%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]P264, P264+P265, P280, P302+P352, P305+P351+P338, P321, P332+P317, P337+P317, and P362+P364 (click each P-code to see the statement)Aggregated GHS information provided per 44 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Reported as not meeting GHS hazard criteria per 2 of 44 reports by companies.There are 3 notifications provided by 42 of 44 reports by companies with hazard statement code(s).Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. |
|---|---|
| 규제 정보 | Status: Active Update: 06-03-2023 https://echa.europa.eu/registration-dossier/-/registered-dossier/5699Status: Active Update: 06-09-2018 https://echa.europa.eu/registration-dossier/-/registered-dossier/27118Ursodeoxycholic acid: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right. |
| 기타 안전 정보 | IMAP assessments - Cholan-24-oic acid, 3,7-dihydroxy-, (3.alpha.,5.beta.,7.beta.)-: Environment tier I assessmentIMAP assessments - Cholan-24-oic acid, 3,7-dihydroxy-, (3.alpha.,5.beta.,7.beta.)-: Human health tier I assessment |
| Hazard Classes and Categories | Skin Irrit. 2 (95.5%)Eye Irrit. 2A (95.5%) |
| Hepatotoxicity | n multiple clinical trials in a variety of conditions, ursodiol has not been found to cause increases in serum enzyme elevations, worsening of underlying liver disease or clinically apparent liver injury. Nevertheless, there have been rare reports of clinical decompensation in patients with advanced liver disease and cirrhosis started on ursodiol, but the reason for such reactions is not known. In at least one instance, there was recurrence of jaundice on restarting ursodiol. Thus, ursodiol has beneficial effects on several forms of liver disease and has not been convincingly linked to cases of clinically apparent acute liver injury in patients without cirrhosis. There is some concern that ursodiol may be harmful in patients with advanced liver disease (Childs class B and C) and such patients probably should not receive ursodiol. |
용도
용도
Ursodeoxycholic acid (UDCS) is a cell protectant used extensively to mitigate hepatic and biliary diseases. Ursodeoxycholic acid may be used to study its specific activities that range from reduction of cholesterol absorpition, cholesterol gallstone dissolution to suppression of immune response. It is also used as an anticholelithogenic. Epimer with Chenodiol with respect to the hydroxyl group at C7.
일반 설명
Ursodeoxycholic acid (UDCA) is a secondary bile acid that helps regulate cholesterol. Mass spectrometry-based analysis of UDCA is routinely performed in clinical diagnostic testing applications such as neonatal testing of inborn errors of bile acid synthesis, differentiating among types of familial intrahepatic cholestasis, and therapeutic monitoring of patient responses to UDCA therapy. This Certified Spiking Solution is suitable as a starting material in preparation of linearity standards, calibrators, and controls for use in LC-MS/MS and GC/MS bile acid testing methods.